Amyloid-Binding Compounds for Plaque Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with amyloid or amyloid-like proteins, such as Alzheimer's disease and ocular diseases, are limited in effectively targeting amyloid plaque formation and neuronal degradation, with existing medications offering modest benefits and significant side effects, and lack definitive treatments for conditions like age-related macular degeneration and glaucoma.
Innovation Solution
Development of specific compounds that can bind to amyloid proteins, including beta-amyloid, to inhibit aggregation and reduce plaque load, formulated into pharmaceutical compositions for oral, parenteral, or topical administration, designed to cross the blood-brain barrier and target amyloid-related pathological changes in the visual system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat amyloid-related diseases, then some therapeutic benefit is achieved, but side effects are significant and treatment effectiveness is limited
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of compounds to optimize their therapeutic profile. Specifically, the invention uses compounds with specific molecular weights (300-800 Daltons), particular functional groups, and defined lipophilicity parameters (logP values) to enhance blood-brain barrier penetration while maintaining amyloid-binding affinity. This systematic variation of chemical parameters enables achieving both high efficacy and reduced side effects
Solution Approach 2:
The patent utilizes intermediary compounds that specifically bind to amyloid proteins as mediators between the administered drug and the pathological amyloid deposits. These compounds act as intermediaries by first crossing the blood-brain barrier, then binding to amyloid fibrils with high affinity, and facilitating amyloid clearance or preventing further aggregation, thereby transmitting the therapeutic effect from the systemic circulation to the central nervous system targets
2Quantity of substance
If current treatments are applied to target amyloid plaque formation, then modest benefits are achieved, but the ability to effectively reduce plaque load is insufficient
Solution Approach 1:
The patent applies the extraction principle by designing compounds that specifically bind to and extract amyloid proteins from plaques. The compounds have high affinity for amyloid fibrils and can selectively remove or solubilize amyloid deposits from neural tissue without affecting normal proteins. This selective extraction capability enables effective reduction of plaque burden while preserving healthy tissue
Solution Approach 2:
The patent employs preliminary action by administering compounds that prevent amyloid aggregation before plaques form or early in the disease process. The compounds interfere with the nucleation and elongation steps of amyloid formation, preventing the development of large plaque deposits. This preventive approach is more effective than attempting to remove established plaques
3Ease of operation
If medications are designed to cross the blood-brain barrier, then central nervous system targeting is achieved, but drug delivery efficiency is reduced
Solution Approach 1:
The patent systematically optimizes molecular parameters to achieve optimal blood-brain barrier penetration. Compounds are designed with specific molecular weight ranges (300-800 Daltons), controlled lipophilicity (logP values between 1-4), and particular hydrogen bonding characteristics. These parameter optimizations enable efficient passive diffusion across the blood-brain barrier while maintaining sufficient solubility in aqueous circulation
Solution Approach 2:
The patent employs composite molecular structures that combine hydrophilic and hydrophobic moieties in specific ratios and configurations. These amphipathic compounds can interact with both the aqueous blood plasma and the lipid-rich blood-brain barrier membrane, facilitating efficient transport. The composite structure includes amyloid-binding domains and membrane-permeation domains working in concert
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce amyloid plaque burden, inhibit aggregation, and alleviate symptoms associated with amyloid-related diseases, offering improved treatment options for neurological and ocular disorders with a reduced risk of side effects and enhanced cognitive memory retention.
Implementation Method 1
specific compounds that can bind to amyloid proteins, including beta-amyloid, to inhibit aggregation and reduce plaque load
Data Source
AI summary
The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.